Full-Time

Translational Medical Scientist

Posted on 12/20/2024

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Biotechnology
Healthcare

Compensation Overview

$92.2k - $115.2kAnnually

Senior, Expert

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
R
SQL
Requirements
  • The candidate must have a Ph.D. in Molecular Biology, Genomics, Bioinformatics, Oncology, Genetics, Molecular Biology (or a related discipline)
  • Solid scientific understanding or education background in cancer biology and clinical oncology
  • Knowledge of cancer from both a molecular genomics and clinical perspective
  • Working knowledge of genomics sequencing analysis techniques
  • Knowledge of data mining and statistical analysis tools and methodologies.
  • Strong knowledge of R, experience in using packages ggplot2, data.table, Bioconductor
  • Familiarity with querying relational databases using sql
  • Knowledge and experience in the use and optimization of novel technologies and understand the competitive landscape
  • Ability to thrive in a fast-paced, evolving environment
  • Able to manage competing priorities
  • Ability to proactively identify risks and address with a solutions-oriented approach
  • Superb attention to detail; produces work of exceptional quality and accuracy
  • Proven success in managing collaborative and individual projects
  • Proven interpersonal and communication skills
  • Excellent verbal and written communication skills are required
  • Strong organizational and interpersonal skills will be needed in our fast paced team
Responsibilities
  • Perform genomic and clinical analysis to explore biological, scientific, and clinical questions in oncology and early cancer detection
  • Collaborate with molecular biologists, computational biologists, and statisticians to build research strategies that solve challenging problems
  • Collaborate with external partnerships, include academics, biotechnology companies, pharmaceutical companies
  • Communicating results and findings of analyses to academic researchers and collaborate to publish findings in high impact journals
  • Work with clinicians, product managers, and key opinion leaders to transform product requirements into technical specifications for future oncology and early cancer detection products
  • Work with business and biological teams to understand the research landscape and technology options
  • This role works with PHI on a regular basis and has access to various technologies to access PHI in order to perform the job
  • An employee must complete training relating to HIPAA/PHI privacy, General Policies and Procedure Compliance training and security training as soon as possible but no later than the first 30 days of hire
  • Must maintain a current status on Natera training requirements
  • An employee must pass a post-offer criminal background check

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and monitor organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services, directly to healthcare providers and patients. The company's goal is to improve patient care through precise genetic insights that support informed medical decisions.

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

9%

1 year growth

25%

2 year growth

66%
Simplify Jobs

Simplify's Take

What believers are saying

  • Signatera test detects cancer recurrence earlier than traditional imaging.
  • Prospera Heart's DQS improves accuracy in transplant rejection risk assessment.
  • Natera's extensive cfDNA experience supports innovation across multiple health sectors.

What critics are saying

  • Hindenburg report alleges deceptive sales practices, risking legal and reputational issues.
  • New testing features may face slow adoption by healthcare providers.
  • Fetal RhD test demand may decline post-RhIg shortage, affecting sales.

What makes Natera unique

  • Natera's cfDNA technology is pivotal in prenatal and cancer diagnostics.
  • The Donor Quantity Score (DQS) enhances Prospera Heart's transplant rejection detection.
  • Natera's fetal RhD test addresses RhIg shortages, offering unique prenatal solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks